(redirected from chronic lymphocytic leukemia)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Encyclopedia, Wikipedia.


Fifth letter of a Nasdaq stock symbol specifying that it is the third preferred bond of the company.


1. On a stock transaction table, a symbol indicating that a dividend was paid after a stock split.

2. A symbol appearing next to a bond listed on NASDAQ indicating that the bond is a company's third preferred bond. All NASDAQ listings use a four-letter abbreviation; if the letter "I" follows the abbreviation, this indicates that the security being traded is a third preferred bond.


Used in the dividend column of stock transaction tables to indicate that the dividend was paid after a stock dividend or split: Lehigh s.20i.
Mentioned in ?
References in periodicals archive ?
Chronic lymphocytic leukemia with coexistent Hodgkin's disease.
Impaired T-cell transformation in chronic lymphocytic leukemia (CLL): Demonstration of a blastogenesis inhibitory factor.
Identify and understand important and diverse types of therapeutics under development for B-Cell Chronic Lymphocytic Leukemia.
About Chronic Lymphocytic Leukemia (CLL) The prevalence of CLL/SLL is approximately 115,000 patients in the United States,[1] with approximately 16,000 newly diagnosed patients every year.
Coverage of the Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL) pipeline on the basis of route of administration and molecule type.
LEAVE YOUR QUERIES @ B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H2 2015
A snapshot of the global therapeutic scenario for Chronic Lymphocytic Leukemia (CLL).
The primary endpoint of the study was PFS as assessed by an Independent Review Committee according to the International Workshop on Chronic Lymphocytic Leukemia (iWCLL) 2008 criteria, with modification for treatment-related lymphocytosis.
Chronic lymphocytic leukemia is divided by the type of lymphocyte involved, such as B-cell or T-cell.

Full browser ?